EMBC (Embecta) Net Profit

Corporate emblem and logo of embecta.com (EMBC)

Embecta Corp. (EMBC) produces diabetes therapy supplies, yet faces declining demand for pens due to the GLP-1 trend and pricing pressure, as confirmed by the GURU.Markets quotes below, where profit stands at 0.09. The production of needles and syringes provides stability through the ability to regularly increase prices. Large-scale manufacturing and major pharmacy partnerships protect the brand's position from competition.

EMBC: Embecta Corp. Net Profit 04/28/2023 - 10/29/2026

Financial and market metric breakdowns for Embecta (EMBC)

- current quotes and average value forecast:
Market Chart Embecta Health|EMBC - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization Embecta Health|EMBC - Total Company Value
- book capitalization data:
Net Assets per Single Share Embecta|EMBC - Book Capitalization|Market Capitalization to Book Value embecta.com|EMBC - Cumulative Company Assets
- debt and liquidity details:
Aggregate Debt to Equity Embecta Corp.|EMBC - Long-Term Debt to Capital|Current Liabilities to Capital Embecta Corp|EMBC - Company Aggregate Debts|Debt to Book Value Ratio Embecta Health|EMBC - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Embecta|Quick Liquidity Indicator embecta.com
- earnings and valuation multiples information:
EMBC - Net Profit
Fundamental valuation:Embecta Health
Product sample of Embecta Corp.

Embecta Corp. maintains a strong position in the global medical device market. Stable demand for humanitarian products directly determines the cash flow dynamics that shape the final financial result. The company's profit reflects the net remaining funds after deducting all operating and tax obligations. Daily monitoring of this metric allows for the prompt identification of discrepancies in corporate reporting. Analyzing the company's profit helps investors assess the business's resilience to cyclical risks.

Key competitors

BSX - Net Financial Result|EW (Edwards Lifesciences) - Net Profit|Net Profit resmed.com|Company Net Income Insulet (PODD)|Company Net Income ZBH (Zimmer Biomet Holdings)|Net Profit COO (CooperVision)|Net Financial Result Align Corp (ALGN)|GMED: Net Income|Profit After Tax TMDX|ATEC: Net Profit|Company Net Income CryoLife (AORT)|ENOV (DJO Global) - Net Profit|Company Profit IART (Integra LifeSciences Inc.)|Net Income ESTA (Establishment Labs)|BBNX (betabionics.com) - Final Profit|Company Net Income IRADIMED IRMD|TNDM - Net Income|Axogen Corp - Net Profit|Company Net Income SI-BONE Medical|OFIX: Net Profit|Company Profit BVS|KIDS (OrthoPediatrics Corp) - Net Profit|Treace Medical Concepts Inc (TMCI) - Net Financial Result|Net Profit SRTA|Net Income Carlsmed Medical CARL|Net Profit RXST (RxSight, Inc.)|Net Profit ClearPoint Neuro Inc. CLPT|STXS - Company Net Income|STIM: Company Net Income|SGHT (Sight Sciences, Inc) - Net Income|Orchestra BioMed Inc. - Final Profit|ANIK (Anika Therapeutics Inc.) - Net Profit|Company Net Income inspiremd.com NSPR|Company Net Income Jin Medical International (ZJYL)|vivani.com (VANI) - Annual Net Income|Xtant Medical - Net Income|Net Profit NeuroOne Medical Technologies Corp. NMTC|Modular Med - Net Profit|Net Financial Result myomo.com MYO|Envoy Medical (COCH) - Company Net Income|Profit After Tax VVOS (Vivos Therapeutics Inc.)|Company Net Income enVVeno|Net Income SINTX Technologies (SINT)|Net Profit TNON|LFWD - Company Net Income|Company Net Income Autonomix Medical AMIX|IVF: Company Profit|BBLG: Net Income|Axonics, Inc - Profit After Payment of Taxes|BIOL: Net Profit|Company Net Income Dynatronics (DYNT)|Company Net Income Paragon 28 Inc.|Net Income INVO Bio (INVO)